Rabro™

Therapeutic Segment:
Anti-ulcerant

Generic Name:
Rabeprazole

Description:
Rabeprazole sodium is a white to slightly yellowish white solid. Rabro is available for oral administration as delayed release, enteric-coated tablets. The active ingredient in Rabro delayed release tablets is rabeprazole sodium, which is a proton pump inhibitor.

Indication:
Healing of Erosive or Ulcerative GERD in Adults. Rabro delayed release tablets are indicated for short term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8 week course of Rabro may be considered.

Formulation:

• Tablets

Strength:

• 10mg
• 20mg

Pack Size:

• 1’s